Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Hans E. Johnsen"'
Autor:
Andreas K. Øvlisen, Anders Oest, Mette D. Bendtsen, John Bæch, Preben Johansen, Line S. Lynggaard, Ingolf Mølle, Thomas B. Mortensen, Duruta Weber, Gideon Ertner, Claudia Schöllkopf, Jesper Q. Thomassen, Ove Juul Nielsen, Lene Sofie Granfeldt Østgård, Martin Bøgsted, Karen Dybkær, Hans E. Johnsen, Marianne T. Severinsen
Publikováno v:
Blood Advances, Vol 2, Iss 5, Pp 559-564 (2018)
Abstract: Stringent complete remission (sCR) of acute myeloid leukemia is defined as normal hematopoiesis after therapy. Less sCR, including non-sCR, was introduced as insufficient blood platelet, neutrophil, or erythrocyte recovery. These latter cha
Externí odkaz:
https://doaj.org/article/61ca51595feb468eb88a90fd0febbb7f
Autor:
Fiona M. Ross, Hervé Avet-Loiseau, Geneviève Ameye, Norma C. Gutiérrez, Peter Liebisch, Sheila O’Connor, Klara Dalva, Sonia Fabris, Adele M. Testi, Marie Jarosova, Clare Hodkinson, Anna Collin, Gitte Kerndrup, Petr Kuglik, Dariusz Ladon, Paolo Bernasconi, Brigitte Maes, Zuzana Zemanova, Kyra Michalova, Lucienne Michau, Kai Neben, N. Emil U. Hermansen, Katrina Rack, Alberto Rocci, Rebecca Protheroe, Laura Chiecchio, Hélène A Poirel, Pieter Sonneveld, Mette Nyegaard, Hans E. Johnsen
Publikováno v:
Haematologica, Vol 97, Iss 8 (2012)
The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a
Externí odkaz:
https://doaj.org/article/2e46233e5d1b48ab884e4aedb089e04d
Autor:
Thomas Rasmussen, Jacob Haaber, Inger Marie Dahl, Lene M. Knudsen, Gitte B. Kerndrup, Marianne Lodahl, Hans E. Johnsen, Michael Kuehl
Publikováno v:
Haematologica, Vol 95, Iss 10 (2010)
Background Several laboratories have shown that cells with a memory B-cell phenotype can have the same clonotype as multiple myeloma tumor cells.Design and Methods The aim of this study was to determine whether some memory B cells have the same genet
Externí odkaz:
https://doaj.org/article/8a1a99ad89d14204aef6192ee641e20f
Autor:
Hans E. Johnsen, Lene M. Knudsen, Anne K. Mylin, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Niels Frost Andersen, Torben Plesner, Annette Vangsted, Torben Mourits-Andersen
Publikováno v:
Hematology Reports, Vol 1, Iss 2, Pp e11-e11 (2009)
The impact of chemotherapy resistant B cells in multiple myeloma (MM) needs to be evaluated by in vivo targeted therapy. Here we report the conclusions from a phase II randomized, placebo controlled trial adding fludarabine to the induction with cycl
Externí odkaz:
https://doaj.org/article/907fa9c7ca9a4fb19ec79b759507505c
Autor:
Hans E. Johnsen, Bo Björkstrand, Tobias W. Klausen, Kari Remes, Astrid Gruber, Lene M. Knudsen, Olav J. Bergmann, Stig Lenhoff
Publikováno v:
Hematology Reports, Vol 1, Iss 1, Pp e2-e2 (2009)
Autologous stem cell transplantation is still considered the standard of care in young patients with multiple myeloma (MM). This disease is the most common indication for high-dose therapy (HDT) supported by hematopoietic stem-cell transplantation an
Externí odkaz:
https://doaj.org/article/3ba753057cae4299b0d208e667b731b2
Autor:
Aneire E. Khan, Valentina Gallo, Jakob Linseisen, Rudolf Kaaks, Sabine Rohrmann, Ole Raaschou-Nielsen, Anne Tjønneland, Hans E. Johnsen, Kim Overvad, Manuela M. Bergmann, Heiner Boeing, Vasiliki Benetou, Theodora Psaltopoulou, Antonia Trichopoulou, Giovanna Masala, Amalia Mattiello, Sara Grioni, Rosario Tumino, Roel C.H. Vermeulen, Petra H.M. Peeters, H. Bas Bueno-de-Mesquita, Martine M. Ros, Eiliv Lund, Eva Ardanaz, María-Dolores Chirlaque, Paula Jakszyn, Nerea Larrañaga, Adamina Losada, Nikolaus Becker, Alexandra Nieters, Carmen Martínez-García, Åsa Ågren, Göran Hallmans, Göran Berglund, Jonas Manjer, Naomi E. Allen, Timothy J. Key, Sheila Bingham, Kay Tee Khaw, Nadia Slimani, Pietro Ferrari, Paolo Boffetta, Teresa Norat, Paolo Vineis, Elio Riboli
Publikováno v:
Haematologica, Vol 93, Iss 6 (2008)
Background Non-Hodgkin’s lymphomas are a heterogeneous group of neoplasms arising from the lymphopoietic system including a wide range of subtypes of either B-cell or T-cell lymphomas. The few established risk factors for the development of these n
Externí odkaz:
https://doaj.org/article/a74dd5e296494f21b02d532e82c1e8ed
Autor:
Andy C. Rawstron, Alberto Orfao, Meral Beksac, Ludmila Bezdickova, Rik A. Brooimans, Horia Bumbea, Klara Dalva, Gwenny Fuhler, Jan Gratama, Dirk Hose, Lucie Kovarova, Michael Lioznov, Gema Mateo, Ricardo Morilla, Anne K. Mylin, Paola Omedé, Catherine Pellat-Deceunynck, Martin Perez Andres, Maria Petrucci, Marina Ruggeri, Grzegorz Rymkiewicz, Alexander Schmitz, Martin Schreder, Carine Seynaeve, Martin Spacek, Ruth M. de Tute, Els Van Valckenborgh, Nicky Weston-Bell, Roger G. Owen, Jesús F. San Miguel, Pieter Sonneveld, Hans E. Johnsen
Publikováno v:
Haematologica, Vol 93, Iss 3 (2008)
The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based
Externí odkaz:
https://doaj.org/article/17a5bf9d8e054557b585a0945df8838f
Autor:
Nigel Russell, Rolf Mesters, Joerg Schubert, Marc Boogaerts, Hans E. Johnsen, Consuelo del Canizo, Nigel Baker, Philippa Barker, Tomas Skacel, Norbert Schmitz
Publikováno v:
Haematologica, Vol 93, Iss 3 (2008)
Background Growth factors are frequently used to aid peripheral blood progenitor cell mobilization from bone marrow. This phase 2 study examined the efficacy and safety of pegfilgrastim for mobilizing peripheral blood progenitors cells for autologous
Externí odkaz:
https://doaj.org/article/62179766c6804f98bf9c0e58900ef4cf
Autor:
Liesbeth Bieghs, Malene Brohus, Ida B Kristensen, Niels Abildgaard, Martin Bøgsted, Hans E Johnsen, Cheryl A Conover, Elke De Bruyne, Karin Vanderkerken, Michael T Overgaard, Mette Nyegaard
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0154256 (2016)
Insulin-like growth factor (IGF) signalling plays a key role in homing, progression, and treatment resistance in multiple myeloma (MM). In the extracellular environment, the majority of IGF molecules are bound to one of six IGF-binding proteins (IGFB
Externí odkaz:
https://doaj.org/article/1ec7239160444eb891a0a754cbf06314
Autor:
Michele Cavo, Antonio Palumbo, Sonja Zweegman, Meletios A. Dimopoulos, Roman Hajek, Lucia Pantani, Meral Beksac, Ruth Wester, Hans E. Johnsen, Ulf-Henrik Mellqvist, Maria Teresa Petrucci, Christoph Driessen, Francesco Di Raimondo, Rossella Troia, Annalisa Pezzi, Bronno van der Holt, Ka Lung Wu, Heinz Ludwig, Francesca Gay, Pieter Sonneveld
Publikováno v:
Sonneveld, P, Zweegman, S, Johnsen, H E, Hajek, R, Di Raimondo, F, Palumbo, A, Troia, R, van der Holt, B, Pantani, L, Gay, F, Wester, R, Driessen, C, Wu, K L, Beksac, M, Ludwig, H, Dimopoulos, M A, Mellqvist, U-H, Pezzi, A, Cavo, M & Petrucci, M T 2018, ' Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). ', Journal of Clinical Oncology, vol. 34, no. 15_suppl, pp. 8000-8000 . https://doi.org/10.1200/jco.2016.34.15_suppl.8000
Journal of Clinical Oncology, 34(15_suppl), 8000-8000. American Society of Clinical Oncology
Journal of Clinical Oncology, 34(15_suppl), 8000-8000. American Society of Clinical Oncology
8000Background: The role of upfront ASCT for newly diagnosed (ND) MM (NDMM) patients (pts) has been questioned in the novel agent era. Methods: A phase 3 study was designed to compare [random (R) 1] 4 cycles of bortezomib-melphalan-prednisone (VMP) v